Related Experiment Video
Updated: Sep 3, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Current and emerging therapies for neuroendocrine prostate cancer
Busola Ruth Alabi1, Shiqin Liu1, Tanya Stoyanova1
1Department of Radiology, Canary Center at Stanford for Cancer Early Detection, Stanford University, Palo Alto, CA 94304, USA.
Abstract:
Neuroendocrine prostate cancer is a histological variant of prostate cancer that is characterized by aggressiveness, poor clinical outcomes, and expression of neuroendocrine markers. Neuroendocrine prostate cancer usually manifests in late-stage prostate cancer patients who have undergone multiple rounds of anti-androgen therapies but can, although rarely, occur in treatment naïve patients de novo. Current therapies to treat neuroendocrine prostate cancer are largely based on their success in treating patients with small cell lung cancer, a lung cancer that shares the neuroendocrine phenotype with neuroendocrine prostate cancer. However, unfortunately these therapies are not durable. In this review, we discuss therapies currently in use to treat neuroendocrine prostate cancer, including platinum-based therapies, taxanes and etoposide. Additionally, we utilize ongoing clinical trials information to identify potential emerging therapies for neuroendocrine prostate cancer. Lastly, we discuss additional potential future opportunities for targeting neuroendocrine prostate cancer.
More Related Videos
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
08:34Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...